xCures has collaborated with Biomed Valley Discoveries to facilitate expanded access to ulixertinib

This expanded access protocol is intended to provide compassionate use of ulixertinib for participants with advanced, MAPK pathway-altered cancers who have exhausted available standard therapies.

If you or your doctor believes you or someone for whom you are their Legally Authorized Representative may be eligible to enroll, please register. Registration takes about 5 minutes to complete.

Once you do so, the xCures team will coordinate enrollment in the expanded access protocol and/or offer alternative treatment assistance, as appropriate.